Aldeyra Therapeutics Posts Wider Q2 Loss
1:51PM ET 8/05/2022 MT NewswiresAldeyra Therapeutics (ALDX) reported Friday a Q2 net loss per share of $0.30, widening from a loss of $0.28 a year earlier. Analysts polled by Capital IQ...
-- Earnings Flash (ALDX) ALDEYRA THERAPEUTICS Posts Q2 Loss $-0.30
7:01AM ET 8/05/2022 MT Newswires...
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday
9:05AM ET 7/12/2022 MT NewswiresHealth care stocks were leaning lower premarket Tuesday. The Health Care SPDR (XLV) was down 0.33% and the iShares NASDAQ Biotechnology Index (IBB) was...
Sector Update: Health Care
8:47AM ET 7/12/2022 MT NewswiresHealth care stocks were declining premarket Tuesday. The Health Care SPDR (XLV) was down 0.35% and the iShares NASDAQ Biotechnology Index (IBB) was...
Aldeyra Therapeutics Says its Dry Eye Disease Therapeutic Reproxalap Meets Primary Endpoints of Clinical Trial
7:29AM ET 7/12/2022 MT NewswiresAldeyra Therapeutics (ALDX) said Tuesday its opthalmic solution candidate, reproxalap, for the treatment of dry eye disease was statistically superior to...
--Aldeyra Therapeutics to Report Reproxalap Results from Dry Eye Disease Clinical Trial on Tuesday
4:19PM ET 7/11/2022 MT NewswiresPrice: 4.6, Change: +0.13, Percent Change: +2.91 ...
--Berenberg Bank Terminates Coverage of 85 Companies in Consumer Discretionary, Healthcare, Industrial Tech, REIT, Software and IT Services Sectors
8:41AM ET 7/01/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
--Oppenheimer Adjusts Aldeyra Therapeutics Price Target to $11 From $10, Maintains Outperform Rating
10:07AM ET 6/09/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Citigroup Adjusts Aldeyra Therapeutics' Price Target to $26 From $21, Reiterates Buy Rating
7:23AM ET 6/09/2022 MT NewswiresAldeyra Therapeutics (ALDX) has an average rating of buy and price targets ranging from $11 to $30, according to analysts polled by Capital IQ. (MT...
Aldeyra Says Reproxalap Meets Primary Endpoint in Late-Stage Trial for Dry Eye Disease, Plans to Submit NDA
8:05AM ET 6/08/2022 MT NewswiresAldeyra Therapeutics (ALDX) said Wednesday that its late-stage clinical trial of reproxalap for the potential treatment of dry eye disease has met its...